Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001641172-25-009044
Filing Date
2025-05-07
Accepted
2025-05-07 16:30:52
Documents
76
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q form10-q.htm   iXBRL 10-Q 646087
2 EX-31.1 ex31-1.htm EX-31.1 11552
3 EX-31.2 ex31-2.htm EX-31.2 11725
4 EX-32.1 ex32-1.htm EX-32.1 6774
5 EX-32.2 ex32-2.htm EX-32.2 6926
6 GRAPHIC form10-q_001.jpg GRAPHIC 5675
  Complete submission text file 0001641172-25-009044.txt   4600141

Data Files

Seq Description Document Type Size
7 XBRL SCHEMA FILE erna-20250331.xsd EX-101.SCH 40154
8 XBRL CALCULATION FILE erna-20250331_cal.xml EX-101.CAL 63195
9 XBRL DEFINITION FILE erna-20250331_def.xml EX-101.DEF 175873
10 XBRL LABEL FILE erna-20250331_lab.xml EX-101.LAB 351621
11 XBRL PRESENTATION FILE erna-20250331_pre.xml EX-101.PRE 308207
78 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 499844
Mailing Address 10531 4S COMMONS DRIVE SUITE 166-550 SAN DIEGO CA 92127
Business Address 1035 CAMBRIDGE STREET SUITE 18A CAMBRIDGE MA 02141 (617) 798-6700
Ernexa Therapeutics Inc. (Filer) CIK: 0000748592 (see all company filings)

EIN.: 311103425 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-11460 | Film No.: 25921954
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)